Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Pharnext

    MCap

    1m

    Last close

    EUR0.10

    ▲ 0.03 (42.86%)

    MGI – Media and Games Invest

    MCap

    EUR235m

    Last close

    EUR1.50

    ▲ 0.35 (30.21%)

    AGBA

    MCap

    USD211m

    Last close

    USD2.83

    ▲ 0.48 (20.43%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Newron Pharmaceuticals (SIX: NWRN)

Last close As at 30/04/2024

CHF8.21

▲ 0.57 (7.46%)

Market capitalisation

CHF153m

Newron Pharmaceuticals is focused on the central nervous system. Xadago for Parkinson’s disease (PD) is sold in Europe, Japan, the United States and other regions. Evenamide, a novel schizophrenia add-on therapy, is involved in a Phase II/III trial programme targeting schizophrenia.

Xadago is marketed as an add-on to levodopa therapy in PD. It is currently sold in Europe, Japan, the United States and other territories. Generic manufacturers have notified the FDA of their intention to file generic Xadago products. Newron is contesting these filings. Xadago is currently patent protected until at least 2027.

Latest Insights

View More

Healthcare | Flash note

Newron Pharmaceuticals — Evenamide notches up another win (study 008A)

Healthcare | Update

Newron Pharmaceuticals — Evenamide set for a pivotal year

Healthcare | Flash note

Newron Pharmaceuticals — Operational flexibility with new/updated financing

Healthcare | Update

Newron Pharmaceuticals — TRS data green-lights evenamide Phase III plans
Visit Website

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Nidhi Singh

Nidhi Singh

Analyst

Arron Aatkar

Associate analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Key Management

  • Marco Caremi

    Executive VP of Business Development

  • Stefan Weber

    CEO

Balance Sheet

Forecast net cash (€m)

29.1

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 5.8 6.3 84.9
Relative 10.2 7.0 87.8
52 week high/low CHF10.4/CHF3.9

Financials

Newron Pharmaceuticals has shared positive top-line data for its evenamide programme from its potentially pivotal Phase II/III trial (study 008A) in patients with poorly managed schizophrenia on current antipsychotic therapy, but not considered treatment-resistant. The trial met its primary endpoint of improvement on the Positive and Negative Syndrome Scale (PANSS) score from baseline, and the key secondary endpoint of improvement on the Clinical Global Impression of Severity (CGI-S) scale. Statistical significance was met in both, consolidating the already strong results from the Phase II trial (study 014/015) in treatment-resistant schizophrenia (TRS). Management plans to follow this up with a potentially pivotal Phase III study in TRS (study 017), which, subject to final agreement by potential partners and regulatory bodies, could commence within 2024.

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (c) P/E (x) P/CF (x)
2022A 6.1 (12.6) (17.0) (95.34) N/A N/A
2023A 9.1 (11.2) (16.0) (89.81) N/A N/A
2024E 24.3 2.1 (2.6) (14.12) N/A N/A
2025E 27.1 3.3 (0.8) (4.31) N/A N/A

Research

Update

Healthcare

Newron Pharmaceuticals — Evenamide set for a pivotal year

Flash note

Healthcare

Newron Pharmaceuticals — Operational flexibility with new/updated financing

Healthcare

Flash note

Newron Pharmaceuticals — Evenamide notches up another win (study 008A)
View All

Further insights

insight

Healthcare

Newron Pharmaceuticals: EKF 2023 QuickView

insight

Healthcare

Deutsches Eigenkapitalforum (EKF) 2022 healthcare

insight

Consumer

Deutsches Eigenkapitalforum (EKF) 2022

Analyst of the week

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

sromanoff@edisongroup.com 020 3077 5700
Read latest

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free